| 9187468 |
Topical ocular analgesic agents |
Martha E. Gadd, Karen C. David, Kenneth C. Appell, Mark R. Hellberg |
2015-11-17 |
$12,726,000 |
| 8067405 |
Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
Robert J. Collier, Mark R. Hellberg |
2011-11-29 |
$28,127,000 |
| 8034839 |
Method of treating ocular allergy |
Clay Beauregard |
2011-10-11 |
|
| 8003635 |
Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
Robert J. Collier, Mark R. Hellberg |
2011-08-23 |
$9,245,000 |
| 7923471 |
Method of treating dry eye disorders and uveitis |
Mark R. Hellberg, Daniel A. Gamache |
2011-04-12 |
|
| 7879905 |
5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses |
Mark R. Hellberg, David P. Bingaman, Daniel A. Gamache |
2011-02-01 |
$36,923,000 |
| 7807363 |
Superoxide dismutase-2 expression for glaucoma diagnosis |
Wan-Heng Wang, Loretta McNatt, Abbot F. Clark |
2010-10-05 |
$50,560,000 |
| 7759333 |
Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
Robert J. Collier, Mark R. Hellberg |
2010-07-20 |
$39,974,000 |
| 7754706 |
Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
Robert J. Collier, Mark R. Hellberg |
2010-07-13 |
$207,888,000 |
| 7745461 |
Method of treating dry eye disorders |
— |
2010-06-29 |
$114,122,000 |
| 7687539 |
Method of treating ocular allergy |
Clay Beauregard |
2010-03-30 |
$318,166,000 |
| 7625927 |
Method of treating glaucoma |
Iok-Hou Pang |
2009-12-01 |
$106,468,000 |
| 7112588 |
Use of proteasome inhibitors to treat dry eye disorders |
Mark R. Hellberg |
2006-09-26 |
$130,199,000 |
| 7060728 |
11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders |
David B. Belanger |
2006-06-13 |
$68,505,000 |
| 6803385 |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders |
Mark R. Hellberg, John R. Falck, Raymond E. Conrow |
2004-10-12 |
$140,063,000 |
| 6750250 |
11,12-oxidoarachidonic acid derivatives and methods of their use in treating dry eye disorders |
David B. Belanger |
2004-06-15 |
$142,977,000 |
| 6740674 |
Use of proteasome inhibitors to treat dry eye disorders |
Mark R. Hellberg |
2004-05-25 |
$47,610,000 |
| 6723748 |
Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
John E. Bishop, Verney L. Sallee, Paul W. Zinke |
2004-04-20 |
$67,837,000 |
| 6680339 |
15-fluoro prostaglandins as ocular hypotensives |
Mark R. Hellberg, Paul W. Zinke |
2004-01-20 |
$61,588,000 |
| 6649653 |
15-fluoro prostaglandins as ocular hypotensives |
Mark R. Hellberg, Paul W. Zinke |
2003-11-18 |
$25,764,000 |
| 6645978 |
Lipoxin A4 and its analogs for the treatment of dry eye |
Daniel A. Gamache, Gustav Graff, Mark R. Hellberg, John M. Yanni |
2003-11-11 |
$29,930,000 |
| 6576663 |
6-Keto prostaglandin F1&agr; and analogs for treating dry eye |
— |
2003-06-10 |
$61,433,000 |
| 6552084 |
Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders |
Mark R. Hellberg, John R. Falck, Raymond E. Conrow |
2003-04-22 |
$130,052,000 |
| 6545045 |
Prostaglandin E agonists for treatment of glaucoma |
Najam A. Sharif, Brenda W. Griffin |
2003-04-08 |
$139,397,000 |
| 6462080 |
Prostaglandin E receptor agonists for treatment of dry eye |
— |
2002-10-08 |
$27,050,000 |
